$8MSeed, 7 January 2026
Series Seed 2 announced alongside an $8.4M ARPA-H contract to advance the platform toward clinic.
- Amount
- $8M
- Stage
- Seed
- Announced
- 7 January 2026
- Lead
- Boehringer Ingelheim Venture Fund
- Other investors
- Delos Capital, Recordati
- Use of funds
- Series Seed 2 announced alongside an $8.4M ARPA-H contract to advance the platform toward clinic.
- Checked
- Announced by the company
- Sources
- STRM.BIO raises $8M Series Seed 2 for non-viral gene delivery prnewswire.com
STRM.BIO raises $8M Series Seed 2 for non-viral gene delivery pulse2.com